NAD+: What the Clinical Trials Actually Show
Last updated: March 2026
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme essential to cellular energy metabolism, DNA repair, and sirtuin signaling. The review this guide draws on describes NAD+ levels falling with age, attributing it to reduced biosynthesis, increased consumption (by enzymes such as PARPs and CD38), or both. Human trials show NMN and NR raise NAD+ levels, with short-term tolerability reported.
🧪 Buy NAD+ at Swiss Chems →Build your own printable peptide tracker
A personalized injection log, weekly dosing schedule and dated calendar: your compounds filled in, ready to print. Free to build and preview; $5/month to unlock printing.
What Is NAD+?
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell. First described in 1906 by Arthur Harden and William John Young, in yeast extract. A 2025 review describes it as a central metabolic cofactor and signaling molecule involved in energy metabolism, mitochondrial function, inflammation, and DNA repair.
Energy Metabolism
Central to converting food into cellular energy (ATP). Required by mitochondria for the electron transport chain.
DNA Repair
A critical co-substrate for DNA-repair enzymes, particularly PARPs, which are major consumers of NAD+ (Khatri et al. 2025).
Cellular Signaling
Sirtuins are NAD+-dependent enzymes; the 2025 review describes sirtuins and PARPs as central to maintaining genomic integrity and chromatin structure.
Cellular Cleanup
Helps regulate autophagy, your cells' garbage collection system that removes damaged components and recycles them.
Why NAD+ Declines With Age
The 2025 review attributes the age-related fall in NAD+ to reduced biosynthesis, increased consumption, or both. This page cites no dataset for how large that decline is at any given age.
Aging is associated with a gradual decline of intracellular NAD+ levels due to reduced NAD+ biosynthesis, increased NAD+ consumption or both.
— Khatri, Abdellatif & Sedej, Geromedicine 2025 (Figure 2 legend)
The Four Precursor Pathways
The 2025 review calls precursor supplementation the most practical and extensively studied way to raise NAD+, while noting it remains unclear how different precursors are absorbed, converted, and delivered to tissues in humans. Four main compounds have been studied in humans, each entering the biosynthesis pathway at a different step.
NMN (Nicotinamide Mononucleotide)
Direct precursor to NAD+. One enzymatic step away.
NR (Nicotinamide Riboside)
Patented as Niagen/Tru Niagen. Two steps from NAD+.
Niacin / Nicotinic Acid (NA)
The cheapest NAD+ precursor. Vitamin B3 you've had your whole life.
NAM (Nicotinamide)
Most common dietary form. Found in fortified foods everywhere.
What the Clinical Trials Actually Found
From the 2025 review by Khatri, Abdellatif & Sedej (Geromedicine). Here's what the human trial evidence it summarizes supports.
Consistently Demonstrated
- Oral NR and NMN were generally well tolerated in completed trials
- Oral NR and NMN do raise blood NAD+ levels measurably
- No serious adverse effects in completed oral NR/NMN trials
Mixed or Limited
- Physical performance improvements: modest and inconsistent
- Muscle mass/strength effects: non-significant in meta-analysis
- Cognitive benefits: not yet demonstrated in large trials
- Many trials focused on safety, not clinical outcomes
Not Yet Demonstrated
- Lifespan extension in humans
- Reversal of biological aging
- Consistent clinical outcomes across large populations
Despite extensive preclinical evidence demonstrating the benefits of NAD+, clinical studies still lag behind. To date, a limited number of trials have been completed, and many of these focused on safety, tolerability, and the ability of NAD+ precursors to increase NAD+ bioavailability.
— Khatri, Abdellatif & Sedej, Geromedicine 2025
Not All NAD+ Is Equal
Delivery route is a major theme of Dr. Craig Koniver's Huberman Lab interview. The order below reflects his clinical opinion, not head-to-head trial or pharmacokinetic data. None is cited on this page.
IV Infusion: Koniver's Top Pick (Opinion)
Koniver's #1 pick, based on his clinical practice. No IV NAD+ trial is cited here, and clinical benefits of NAD+ boosting are not yet demonstrated in trials.
Injection (SubQ/IM)
Mentioned as an alternative for those who can't access IV infusions. No pharmacokinetic comparison with oral forms is cited on this page.
NMN (Oral): Best Oral Option
Best oral option per Koniver. NMN sits one step closer to NAD+ in the biosynthesis pathway than NR; no head-to-head trial comparing how well the two convert is cited on this page.
NR (Oral)
Raises blood NAD+ in human trials. Koniver says it may reduce inflammation but the data is sparse, and he rates it less effective than NMN. Two steps from NAD+.
NAD+ Direct (Oral)
Ranked last in Koniver's order. No pharmacokinetic data on oral NAD+ absorption is cited on this page.
"If I had to pick one thing for people, engaging in NAD would be it."
What Koniver & Huberman Actually Said
Dr. Craig Koniver is a functional medicine physician who uses IV NAD+ in his practice. This section summarizes his October 2024 appearance on Huberman Lab: clinician opinion, not trial evidence.
IV NAD+: Clinical Reality
Koniver describes the change he sees in patients on IV NAD+ as "almost inexplicable." That is a clinician's anecdote; no IV NAD+ trial is cited on this page.
The Oral Hierarchy
Koniver's clear preference: NMN over NR over direct NAD+ for oral supplementation. His reasoning: proximity to NAD+ in the biosynthesis pathway. That fewer enzymatic steps means better conversion is his reasoning, not a trial finding cited here.
Who Might Benefit (Opinion)
Koniver's view is that people with lower baseline NAD+ (older, sick, or metabolically compromised) have the most room to gain, and healthy, fit individuals may have little room for improvement. That is clinician opinion. No trial on this page shows who benefits, and clinical benefits of NAD+ boosting are not yet demonstrated.
Hair & Nails (Anecdote)
Koniver says patients on NMN report faster hair and nail growth. That is a clinician's anecdote, not a validated biomarker. No study of it is cited on this page.
NAD+ Precursors in Food
The main dietary NAD+ precursors are nicotinamide and nicotinic acid (niacin), often added to fortified staples like rice, flour, cereals, bread, pasta and milk (Khatri et al. 2025). The foods below are commonly listed niacin sources; this page cites no per-food content data.
Safety: What the Trials Show
In completed human trials of oral NR and NMN, no serious adverse effects have been reported. Niacin and IV NAD+ have their own considerations, below.
Oral NR / NMN: Well Tolerated The 2025 review (Khatri et al.) finds oral NAD+ precursors generally safe and well tolerated, with no indications of serious side effects. A minority of trials reported mild side effects, e.g. minor gastrointestinal symptoms, nausea, and diarrhea with NR combined with pterostilbene. Large, long-term NR/NMN trials remain scarce.
IV NAD+: No Trial Safety Data Cited No IV NAD+ safety data is cited on this page. The trial safety findings here cover oral NR/NMN only, not IV NAD+.
Niacin: Flushing is Common Skin flushing (redness, warmth, itching) is well-documented at higher doses.
Oral NR / NMN: No Serious Adverse Effects Reported The 2025 review (Khatri et al.) reports no serious adverse events in completed human trials of oral NR and NMN, supporting short-term tolerability for those two precursors. It is not a safety finding for niacin or IV NAD+.
Key Takeaways
Where does the science actually land? Here's the honest split between what's established and what's still speculation.
What We Know
- Oral precursors (NR, NMN) raise blood NAD+ levels, with no serious adverse events reported in short-term trials
- Oral NR/NMN showed no serious adverse effects in completed human trials
- NAD+ is central to energy, DNA repair, and cellular signaling
What We Don't Know Yet
- Whether raising NAD+ in healthy people produces meaningful clinical benefits
- Long-term effects of chronic supplementation
- The optimal precursor, dose, and delivery route
- Whether supplements actually extend healthspan in humans
- How large the age-related NAD+ decline is (this page cites no dataset for a specific figure)
- Whether IV NAD+ helps: the support is clinician anecdote (Koniver), not trials
- Whether animal findings will translate to humans
Sources
- Khatri S, Abdellatif M, Sedej S. "Clinical evidence for the use of NAD+ precursors to slow aging." Geromedicine. 2025. — Primary review referenced throughout this guide.
- PMC12022230 — NMN and NR skeletal muscle systematic review and meta-analysis (J Cachexia Sarcopenia Muscle). 2025. Pooled NMN trials showed no significant effect on muscle mass, grip strength, or gait speed; the authors concluded current evidence does not support NMN or NR for preserving muscle mass and function in adults with a mean age over 60.
- Rice J, Lautrup S, Fang EF. "NAD(+) Boosting Strategies." Subcell Biochem. 2024 (PMID: 39693020). — Source for NAD+'s 1906 discovery by Harden and Young.
- Bitterman KJ et al. "Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1." J Biol Chem. 2002 (PMID: 12297502).
- FDA GRAS Notice GRN 635 — Nicotinamide riboside chloride (ChromaDex); closed Aug 3, 2016, FDA letter: no questions.
- Huberman Lab Podcast — Dr. Craig Koniver episode, October 2024. Clinical practice perspective on IV NAD+, precursor hierarchy, and practical implementation.
- StatPearls — NAD+ metabolism reference. Comprehensive biochemistry background on biosynthesis pathways, enzyme kinetics, and sirtuin activation.
Related Guides
NAD+ Precursor Supplements
NAD+ precursors discussed in this guide
Affiliate links support HighPeptides at no extra cost.
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 20+ compounds, all in one place.
Get the Guide: $19 (normally $29) →
The Peptide Buyer’s Playbook ($19)
Educational content only. Not medical advice. This page is for informational purposes. NAD+ precursors (NMN, NR) are sold as dietary supplements, not FDA-approved treatments. IV NAD+ is administered in clinical settings. The research reviewed here includes preliminary and observational studies — do not interpret as established treatment guidelines. Always consult with a qualified healthcare provider before starting any supplementation protocol.
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.